Design, Synthesis, In-Silico and Cytotoxic Studies of Indole Derivatives as Potent BCL-2 Inhibitors

Indole-based compounds have emerged as a potentially game-changing category of molecules that specifically target Bcell lymphoma-2 (BCL-2) protein, offering an innovative approach to the management of breast cancer. Breast cancer is a major public health concern globally, necessitating continued research into innovative therapeutic approaches. One such strategy involves inhibiting (BCL-2) protein, which is overexpressed in cancer cells and inhibits apoptosis. A series of indole derivatives (b1-b12) were synthesized using indium chloride as a catalyst in a solvent free conditions to investigate their potential to interfere with BCL-2 mediated survival pathways. Additionally, in silico modeling was employed to identify novel BCL-2 inhibitors and made structural alterations to enhance the selectivity and potency of indole compounds. The efficacy of indole derivatives was determined using an in vitro model that utilizes the MCF cell line. The findings obtained demonstrated that the compound b11 possessed a considerable amount of anticancer activity.